Xeris Biopharma (NASDAQ:XERS) Sets New 12-Month High – Here’s What Happened

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) reached a new 52-week high during trading on Thursday . The company traded as high as $3.42 and last traded at $3.37, with a volume of 932558 shares. The stock had previously closed at $3.34.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of Xeris Biopharma in a research report on Thursday, August 15th.

Xeris Biopharma Stock Up 0.6 %

The business has a 50 day moving average price of $2.94 and a two-hundred day moving average price of $2.47. The stock has a market cap of $500.64 million, a P/E ratio of -7.77 and a beta of 2.70.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. Xeris Biopharma had a negative net margin of 32.83% and a negative return on equity of 16,662.63%. The business had revenue of $48.07 million during the quarter, compared to analyst estimates of $46.80 million. During the same period last year, the firm posted ($0.14) EPS. On average, research analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.4 earnings per share for the current year.

Institutional Trading of Xeris Biopharma

Hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in shares of Xeris Biopharma by 7.3% in the first quarter. Vanguard Group Inc. now owns 7,606,242 shares of the company’s stock worth $16,810,000 after purchasing an additional 519,897 shares during the last quarter. Alpine Global Management LLC increased its stake in Xeris Biopharma by 11.1% in the 1st quarter. Alpine Global Management LLC now owns 300,000 shares of the company’s stock worth $663,000 after acquiring an additional 30,000 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Xeris Biopharma by 9.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 125,635 shares of the company’s stock worth $278,000 after acquiring an additional 10,632 shares in the last quarter. NEA Management Company LLC bought a new position in shares of Xeris Biopharma during the 1st quarter valued at approximately $926,000. Finally, Bayesian Capital Management LP purchased a new position in shares of Xeris Biopharma in the first quarter valued at $37,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.